Ironwood Pharma (IRWD) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
November 4, 2021 7:15 AM EDTLINZESS® (Iinaclotide) prescription demand growth increased 12% year-over-year; LINZESS U.S. net sales of $253 million, an increase of 5% year-over-year
Total revenue of $104 million; U.S. LINZESS collaboration revenue of $100 million
GAAP net income of $56 million and adjusted EBITDA of $65 million; ended Q3 2021 with $574 million in cash and cash equivalents
Expands pipeline by entering into an option agreement with COUR Pharmaceuticals Development Company, Inc. to acquire an exclusive license to develop and commercialize, in the U.S., CNP-104 for the treatment of primary biliary cholangitis (PBC)
BOSTON--(BUSINESS... More
